Exchange: PNK Industry: Biotechnology
-1.54% $1.280
America/New_York / 3 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 5.68 mill |
EPS: | -1.150 |
P/E: | -1.110 |
Earnings Date: | May 15, 2024 |
SharesOutstanding: | 4.44 mill |
Avg Daily Volume: | 0.0120 mill |
RATING 2024-05-03 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.110 | sector: PE -11.58 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -1.110 | industry: PE -107.25 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.296 (-76.84%) $-0.984 |
Date: 2024-05-03 |
Expected Trading Range (DAY) |
---|
$ 1.110 - 1.450 ( +/- 13.28%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Wright Timothy R | Buy | 21 250 | PTIX Common stock Options |
2024-03-25 | Stein Robert Benjamin | Buy | 75 000 | PTIX Common stock Options |
2024-03-25 | Barrage Khalil | Buy | 22 500 | PTIX Common stock Options |
2024-03-25 | Buell Jennifer | Buy | 75 000 | PTIX Common stock Options |
2024-03-25 | Armen Garo H | Buy | 250 000 | PTIX Common stock Options |
INSIDER POWER |
---|
100.00 |
Last 91 transactions |
Buy: 6 726 731 | Sell: 101 568 933 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $1.280 (-1.54% ) |
Volume | 0.0018 mill |
Avg. Vol. | 0.0120 mill |
% of Avg. Vol | 14.58 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.